Understand Benign Prostatic Hypertrophy with Obstruction (BPH with Obstruction). This resource provides information on prostate enlargement with obstruction, focusing on diagnosis, clinical documentation, and medical coding for healthcare professionals. Learn about BPH with obstruction symptoms, treatment, and relevant ICD-10 codes for accurate billing and improved patient care.
Also known as
Diseases of male genital organs
Covers conditions affecting the male reproductive system, including BPH.
Retention of urine
Relates to the inability to completely empty the bladder, a common BPH complication.
Heart failure
Nocturia, a symptom of BPH, can be associated with heart conditions like heart failure.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is there lower urinary tract obstruction due to BPH?
Yes
Is there urinary retention?
No
Do NOT code BPH with obstruction. Code BPH without obstruction (N40.8 or N40.9) or other appropriate diagnosis.
When to use each related code
| Description |
|---|
| Enlarged prostate with blockage of urine flow. |
| Enlarged prostate without blockage of urine flow. |
| Inflammation of the prostate gland. |
Coding BPH with obstruction requires specifying the level (bladder outlet, urethra). Unspecified level leads to coding errors and claim denials.
Documentation must support the obstruction diagnosis. Insufficient clinical evidence (e.g., uroflowmetry) risks inaccurate coding and audits.
Discrepancies between physician notes and diagnostic reports regarding BPH with obstruction can lead to coding inconsistencies and compliance issues.
Q: What are the most effective medical management strategies for Benign Prostatic Hyperplasia with Obstruction in patients with moderate to severe lower urinary tract symptoms?
A: Medical management of Benign Prostatic Hyperplasia (BPH) with Obstruction causing moderate to severe Lower Urinary Tract Symptoms (LUTS) typically involves a combination of approaches. Alpha-blockers (e.g., tamsulosin, alfuzosin) relax smooth muscle in the prostate and bladder neck, improving urine flow. 5-alpha reductase inhibitors (e.g., finasteride, dutasteride) shrink the prostate over time, but significant symptom relief may take several months. Combination therapy with both alpha-blockers and 5-alpha reductase inhibitors can be more effective than monotherapy in patients with larger prostates and higher PSA levels. Phosphodiesterase-5 inhibitors (e.g., tadalafil) can also be considered, particularly in men with erectile dysfunction. Explore how minimally invasive surgical options can complement medical therapy in managing BPH with Obstruction when medical management alone is insufficient.
Q: How do I differentiate Benign Prostatic Hyperplasia with Obstruction from other causes of urinary retention in older male patients, including prostate cancer?
A: Differentiating Benign Prostatic Hyperplasia (BPH) with Obstruction from other causes of urinary retention, such as prostate cancer, requires a thorough clinical evaluation. Digital Rectal Examination (DRE) assesses prostate size, symmetry, and nodularity. While BPH typically presents as a smooth, enlarged prostate, irregularities or hard nodules raise suspicion for prostate cancer. Serum Prostate-Specific Antigen (PSA) levels can be elevated in both BPH and prostate cancer, so PSA alone is not diagnostic. Consider implementing a risk-stratified approach using age, DRE findings, and PSA levels to determine the need for further investigations, such as prostate biopsies or imaging (e.g., transrectal ultrasound, multiparametric MRI). Urinary flow rate measurement and post-void residual urine volume assessment can help quantify the degree of obstruction and aid in differentiating between BPH with Obstruction and other causes of urinary retention. Learn more about the role of advanced imaging in diagnosing prostate cancer.
Patient presents with lower urinary tract symptoms (LUTS) consistent with benign prostatic hypertrophy (BPH) with obstruction. Symptoms include weak urinary stream, hesitancy, straining to void, intermittent stream, incomplete emptying, urgency, frequency, nocturia, and post-void dribbling. Digital rectal examination (DRE) revealed an enlarged, smooth, and non-tender prostate. The patient's International Prostate Symptom Score (IPSS) is 21, indicating moderate to severe symptoms. Urinalysis was negative for infection. Prostate-specific antigen (PSA) level is within normal limits, reducing concern for prostate cancer. Based on the patient's symptoms, DRE findings, and elevated IPSS suggestive of bladder outlet obstruction (BOO) secondary to BPH, a diagnosis of benign prostatic hyperplasia with obstruction is made. Treatment options including watchful waiting, lifestyle modifications (fluid management, timed voiding), alpha-blockers (e.g., tamsulosin), 5-alpha reductase inhibitors (e.g., finasteride), combination therapy, and minimally invasive surgical procedures such as transurethral resection of the prostate (TURP) were discussed. The patient will be started on tamsulosin for symptomatic relief and scheduled for a follow-up appointment to assess treatment response and discuss further management options if necessary. Diagnosis codes for BPH with obstruction (N40.1) and lower urinary tract symptoms (LUTS) (R39.15) are documented for medical billing and coding purposes.